Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) EPS (Basic) (2020 - 2025)

Candel Therapeutics' EPS (Basic) history spans 4 years, with the latest figure at -$0.38 for Q4 2023.

  • On a quarterly basis, EPS (Basic) fell 123.53% to -$0.38 in Q4 2023 year-over-year; TTM through Dec 2023 was -$1.3, a 103.12% decrease, with the full-year FY2025 number at -$0.72, up 58.62% from a year prior.
  • EPS (Basic) hit -$0.38 in Q4 2023 for Candel Therapeutics, down from -$0.29 in the prior quarter.
  • Over the last five years, EPS (Basic) for CADL hit a ceiling of $0.51 in Q4 2021 and a floor of -$1.46 in Q2 2021.
  • Historically, EPS (Basic) has averaged -$0.36 across 4 years, with a median of -$0.3 in 2022.
  • Biggest five-year swings in EPS (Basic): skyrocketed 156.67% in 2021 and later tumbled 900.0% in 2023.
  • Tracing CADL's EPS (Basic) over 4 years: stood at -$0.9 in 2020, then skyrocketed by 156.67% to $0.51 in 2021, then plummeted by 133.33% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
  • Business Quant data shows EPS (Basic) for CADL at -$0.38 in Q4 2023, -$0.29 in Q3 2023, and -$0.33 in Q2 2023.